Wecome Pharmaceutical Co Ltd (300878) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.001x

Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.42 Million ≈ $-208.32K USD) by net assets (CN¥1.03 Billion ≈ $150.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Wecome Pharmaceutical Co Ltd (300878) total market value for the company's overall valuation and market capitalisation.

Wecome Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wecome Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Wecome Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Wecome Pharmaceutical Co Ltd (300878) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Shanghai Hugong Elec(Group) SHG:603131	0.000x
Qingdao Kutesmart Co Ltd SHE:300840	0.022x
SunCoke Energy Inc NYSE:SXC	0.013x
Kim Loong Resources Bhd KLSE:5027	0.060x
Beijing SDL Technology Co Ltd SHE:002658	0.054x
Surya Citra Media Tbk JK:SCMA	0.016x
Chengdu Bright Eye Hospital Co. Ltd. SHE:301239	N/A
ZheJiang RIFA Digital Precision Machinery Co Ltd SHE:002520	0.336x

Annual Cash Flow Conversion Efficiency for Wecome Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wecome Pharmaceutical Co Ltd from 2013 to 2024. View 300878 stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.17 Billion ≈ $171.77 Million	CN¥-27.17 Million ≈ $-3.98 Million	-0.023x	-155.89%
2023-12-31	CN¥1.41 Billion ≈ $205.95 Million	CN¥58.29 Million ≈ $8.53 Million	0.041x	-60.11%
2022-12-31	CN¥1.41 Billion ≈ $206.55 Million	CN¥146.57 Million ≈ $21.45 Million	0.104x	+315.97%
2021-12-31	CN¥1.41 Billion ≈ $206.18 Million	CN¥-67.74 Million ≈ $-9.91 Million	-0.048x	-255.47%
2020-12-31	CN¥1.38 Billion ≈ $202.58 Million	CN¥42.81 Million ≈ $6.26 Million	0.031x	-85.74%
2019-12-31	CN¥519.84 Million ≈ $76.07 Million	CN¥112.76 Million ≈ $16.50 Million	0.217x	-19.08%
2018-12-31	CN¥393.83 Million ≈ $57.63 Million	CN¥105.57 Million ≈ $15.45 Million	0.268x	+182.87%
2017-12-31	CN¥306.05 Million ≈ $44.79 Million	CN¥29.00 Million ≈ $4.24 Million	0.095x	-80.04%
2016-12-31	CN¥210.90 Million ≈ $30.86 Million	CN¥100.15 Million ≈ $14.66 Million	0.475x	+108.41%
2015-12-31	CN¥130.04 Million ≈ $19.03 Million	CN¥29.63 Million ≈ $4.34 Million	0.228x	-61.26%
2014-12-31	CN¥78.22 Million ≈ $11.45 Million	CN¥46.01 Million ≈ $6.73 Million	0.588x	-22.24%
2013-12-31	CN¥34.35 Million ≈ $5.03 Million	CN¥25.98 Million ≈ $3.80 Million	0.756x	--

About Wecome Pharmaceutical Co Ltd

SHE:300878 China Biotechnology

Market Cap

$684.78 Million

CN¥4.68 Billion CNY

Market Cap Rank

#10768 Global

#2954 in China

Share Price

CN¥32.32

Change (1 day)

+2.02%

52-Week Range

CN¥20.68 - CN¥39.45

All Time High

CN¥52.21